Calcipotriol

Generic Name: Calcipotriol

Brand Names: Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 112965-21-6

Unique Ingredient Identifier: 143NQ3779B

Background: Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Indication: For the treatment of moderate plaque psoriasis in adults.

Associated Conditions: Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)

Clinical Trials

COMPARISON of EFFICACY and SAFETY of NARROWBAND UVB with 0.1% TACROLIMUS VS NARROWBAND UVB with 0.005% CALCIPOTRIOL in TREATMENT of VITILIGO

Early Phase 1

Not yet recruiting

Conditions: Vitiligo - Macular Depigmentation
Tacrolimus

Interventions: Drug: Tacrolimus
Drug: Calcipotriol

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-24

Lead Sponsor: Dr ayesha wahid

Target Recruit Count: 60

Registration Number: NCT06880042

Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children with Palmoplantar Wart

Not Applicable

Not yet recruiting

Conditions: Common Warts

Interventions: Drug: Topical 5% fluorouracil cream
Drug: Topical 0.005% calcipotriol ointment
Drug: Placebo

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06737406

Locations: 🇮🇷
Iran, Sari, Mazandaran, Iran, Islamic Republic of

Efficacy of Topical 5-Fluorouracil Vs Calcipotriol As Photodynamic Therapy Pre-treatment for Field Actinic Keratoses

Not Applicable

Not yet recruiting

Conditions: Actinic Keratosis of Face and Scalp
Actinic Keratoses

Interventions: Drug: 5-FU (fluorouracil)
Drug: Calcipotriol

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-12

Lead Sponsor: St Vincent's University Hospital, Ireland

Target Recruit Count: 50

Registration Number: NCT06685588

Combination of Sotyktu and Enstilar for Plaque Psoriasis

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Enstilar
Drug: Deucravacitinib

First Posted Date: 2024-03-25

Last Posted Date: 2024-03-25

Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Target Recruit Count: 30

Registration Number: NCT06329258

Locations: 🇺🇸
Schweiger Derm Group, East Windsor, New Jersey, United States

Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma

Not Applicable

Completed

Conditions: Alopecia Areata

Interventions: Drug: Calcipotriol

First Posted Date: 2023-07-20

Last Posted Date: 2023-10-19

Lead Sponsor: Egymedicalpedia

Target Recruit Count: 80

Registration Number: NCT05954104

Locations: 🇪🇬
Faculty of Dentistary - Aswan University, Aswan, Egypt

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Phase 2

Recruiting

Conditions: Actinic Keratosis

Interventions: Procedure: Biopsy
Drug: Calcipotriene
Drug: Fluorouracil

First Posted Date: 2023-01-26

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT05699603

Locations: 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 1 locations

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Early Phase 1

Withdrawn

Conditions: Central Centrifugal Cicatricial Alopecia

Interventions: Drug: Calcipotriol
Drug: Subject's already prescribed drug

First Posted Date: 2022-06-13

Last Posted Date: 2023-08-31

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT05416320

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

A Phase III Study in Subjects With Mild to Moderate Psoriasis.

Phase 3

Conditions: Mild to Moderate Psoriasis

Interventions: Drug: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Drug: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Other: Placebo

First Posted Date: 2022-02-22

Last Posted Date: 2022-08-10

Lead Sponsor: Lipidor AB

Target Recruit Count: 294

Registration Number: NCT05249972

Locations: 🇮🇳
Lotus Multispeciality Hospital, Ahmedabad, India

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

Phase 4

Active, not recruiting

Conditions: Psoriasis Vulgaris
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Skin and Connective Tissue Diseases

Interventions: Drug: Placebo-vehicle
Drug: Enstilar

First Posted Date: 2022-01-11

Last Posted Date: 2024-01-29

Lead Sponsor: Aarhus University Hospital

Target Recruit Count: 12

Registration Number: NCT05185258

Locations: 🇩🇰
Department of Dermatology, Aarhus N, Region Midtjylland, Denmark

A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

Phase 3

Completed

Conditions: Mild to Moderate Plaque Psoriasis

Interventions: Drug: Calcipotriol/AKVANO, 50 μg/g cutaneous solution
Drug: Calcipotriol Ointment 50 micrograms/g
Other: Placebo

First Posted Date: 2022-01-03

Last Posted Date: 2022-03-03

Lead Sponsor: Cadila Pharnmaceuticals

Target Recruit Count: 278

Registration Number: NCT05174598

Locations: 🇮🇳
Midland Healthcare & Research Center, Lucknow, Uttar Pradesh, India
🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India
🇮🇳
Government Medical College, Aurangabad, Maharashtra, India

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy